Northwest Biotherapeutics Inc.

1.2500-0.0300-2.34%Vol 2.30M1Y Perf 468.49%
Nov 24th, 2020 15:59
BID0.0000 ASK0.0000
Open1.3500 Previous Close1.2800
Pre-Market- After-Market-
 - -%  - -
Target Price
2.00 
Analyst Rating
— — 0.00
Potential %
60.00 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★+     58.23
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.02B 
Earnings Rating
Neutral
Price Range Ratio 52W %
46.84 
Earnings Date
22nd Mar 2019

Today's Price Range

1.23001.3500

52W Range

0.14002.5100

5 Year PE Ratio Range

-1.4000-0.7000

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-4.58%
1 Month
-36.87%
3 Months
271.36%
6 Months
276.51%
1 Year
468.49%
3 Years
362.96%
5 Years
-73.40%
10 Years
0.00%

TickerPriceChg.Chg.%
NWBO1.2500-0.0300-2.34
AAPL115.111.26001.11
GOOG1 768.8834.02001.96
MSFT213.863.75001.78
XOM41.982.62006.66
WFC28.612.31008.78
JNJ143.870.00000.00
FB276.928.49003.16
GE10.450.38003.77
JPM123.325.45004.62
Earnings HistoryEstimateReportedSurprise %
Q03 2017--0.06-
Q02 2017--0.05-
Q01 2017--0.08-
Q04 2016--0.20-
Q02 2016-0.29-0.2031.03
Q01 2016-0.25-0.2020.00
Q03 2015-0.33-0.1651.52
Q02 2015-0.32-0.54-68.75
Earnings Per EndEstimateRevision %Trend
12/2016 QR-0.1966.07Positive
12/2016 QR-0.120.00-
12/2017 FY-0.590.00-
12/2018 FY-0.490.00-
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume2.30M
Shares Outstanding816.92M
Trades Count1.20K
Dollar Volume2.89M
Avg. Volume3.85M
Avg. Weekly Volume1.93M
Avg. Monthly Volume4.83M
Avg. Quarterly Volume8.13M
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
1 (100.00 %)
Moderate Buy
0
0
0 (0.00 %)
Hold
0
0
0 (0.00 %)
Moderate Sell
0
0
0 (0.00 %)
Strong Sell
0
0
0 (0.00 %)
Summary Rating---

Northwest Biotherapeutics Inc.

Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.

CEO: Linda F Powers

Teplephone: +1 240 497-9024

Address: 4800 Montgomery Lane, Bethesda 20814, MD, USA

Number of employees: 14

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

47%53%

Bearish Bullish

45%55%

Bearish Bullish

55%45%

News